Literature DB >> 22523736

Efficacy of ramosetron in male patients with irritable bowel syndrome with diarrhea (neurogastroenterol motil 2011;23:1098-1104).

Bong Ki Cha1, Chang Hwan Choi, Sae Kyung Chang.   

Abstract

Entities:  

Year:  2012        PMID： 22523736      PMCID： PMC3325312          DOI： 10.5056/jnm.2012.18.2.224

Source DB:  PubMed          Journal:  J Neurogastroenterol Motil        ISSN： 2093-0879            Impact factor:   4.924


× No keyword cloud information.
  17 in total

Review 1.  Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel.

Authors:  M D Gershon
Journal:  Aliment Pharmacol Ther       Date:  1999-05       Impact factor: 8.171

Review 2.  AGA technical review on irritable bowel syndrome.

Authors:  Douglas A Drossman; Michael Camilleri; Emeran A Mayer; William E Whitehead
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

3.  Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Authors:  M Camilleri; A R Northcutt; S Kong; G E Dukes; D McSorley; A W Mangel
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

4.  Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.

Authors:  K J Lee; N Y Kim; J K Kwon; K C Huh; O Y Lee; J S Lee; S C Choi; C I Sohn; S J Myung; H J Park; M K Choi; Y T Bak; P L Rhee
Journal:  Neurogastroenterol Motil       Date:  2011-09-15       Impact factor: 3.598

5.  Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design.

Authors:  Ann Marie Trentacosti; Ruyi He; Laurie B Burke; Donna Griebel; Dianne L Kennedy
Journal:  Am J Gastroenterol       Date:  2010-04       Impact factor: 10.864

6.  Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.

Authors:  F Cremonini; S Delgado-Aros; M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2003-02       Impact factor: 3.598

Review 7.  Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.

Authors:  Lin Chang; William D Chey; Lucinda Harris; Kevin Olden; Christina Surawicz; Philip Schoenfeld
Journal:  Am J Gastroenterol       Date:  2006-05       Impact factor: 10.864

8.  A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome.

Authors:  K Matsueda; S Harasawa; M Hongo; N Hiwatashi; D Sasaki
Journal:  Digestion       Date:  2008-06-10       Impact factor: 3.216

9.  A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.

Authors:  Kei Matsueda; Shigeru Harasawa; Michio Hongo; Nobuo Hiwatashi; Daisuke Sasaki
Journal:  Scand J Gastroenterol       Date:  2008       Impact factor: 2.423

Review 10.  Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis.

Authors:  Alexander C Ford; Nicholas J Talley; Brennan M R Spiegel; Amy E Foxx-Orenstein; Lawrence Schiller; Eamonn M M Quigley; Paul Moayyedi
Journal:  BMJ       Date:  2008-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.